Get the latest tech news
New targeted rheumatoid arthritis drug delays disease, reduces flare-ups
A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the immune system without widespread suppression.
A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the immune system without widespread suppression. In the present study, the researchers lab-tested Agg-CLNP on human immune cells from healthy people and RA patients and measured changes in inflammatory markers and immune-regulating proteins. Nonetheless, if it’s successful in future clinical trials, Agg-CLNP could prevent RA in high-risk individuals, help patients stay flare-free for longer when used with existing treatments like abatacept, reduce steroid dependence, and deliver localized immune-calming signals without suppressing the whole immune system.
Or read this on r/tech
